Dr. Montazeri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street
Boston, MA 02114Phone+1 617-724-4000
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2017
Iran University of Medical SciencesClass of 2009
Mount Auburn HospitalResidency, Internal Medicine
Certifications & Licensure
MA State Medical License 2014 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma Start of enrollment: 2021 Aug 02
Roles: Contact, Principal Investigator
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
Roles: Contact
Publications & Presentations
PubMed
- 62 citationsErdafitinib for the treatment of metastatic bladder cancerKamaneh Montazeri, Joaquim Bellmunt
Expert Review of Clinical Pharmacology. 2020-01-01 - 5 citationsSalvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical needKamaneh Montazeri, Guru Sonpavde
Expert Review of Anticancer Therapy. 2021-03-04 - 8 citationsTebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.Kamaneh Montazeri, Vikram Pattanayak, Ryan J Sullivan
Drug Design, Development and Therapy. 2023-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
